gaining weight back after glp 1 will you gain stopping 55% of people who stopped GLP -1s Report back: 3 months off

Food and Drug Administration (FDA) approved an expanded indication for Wegovy (semaglutide 2.4 mg injection) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight

Strasser A, OConnor L, Dixit VM

BREAKING NEWS

13 While native GLP-1 has been targeted as a therapeutic agent due to its favorable effects on glycemia, its clinical utility is limited due to its extremely short half-life

Los datos de los estudios de fase 3a realizados confirmaron esto mismo en sujetos con diabetes tipo 2 e insuficiencia renal (Figura 1), aunque la experiencia en pacientes con enfermedad renal en etapa terminal fue limitada

The most effective strategy is to start with a low dose and increase it gradually, giving your body time to adapt